Screening hemochromatosis and iron overload
2007-06-08 - English

Conventional and new treatment modalities in myelofibrosis
2007-06-08 - English

Conventional therapy of myelofibrosis is essentially palliative. It includes a wait-and-see approach for asymptomatic patients, oral cytolytic drugs such as hydroxyurea for the hyperproliferative forms of the disease, androgens or erythropoietin for the anemia, and...(more)

Molecular pathogenesis of the myeloproliferative diseases
2007-06-08 - English

Diagnosis and classification of MPDs in the JAK2 era
2007-06-08 - English

State-of-the-art treatment of chronic lymphocytic leukemia (CLL)
2007-06-08 - English

Treatment and prevention of alloimmune thrombocytopenias
2007-06-08 - English

Clinical implications of ABL mutational screening
2007-06-08 - English

Mechanisms of iron regulation and of iron deficiency
2007-06-08 - English

Epidemiology of coagulation disorders
2007-06-08 - English

Targeting critical pathways in leukemic stem cells
2007-06-08 - English

Genetics in CLL: Impact for prognosis and treatment decisions
2007-06-08 - English

The role of PET in staging and response assessment
2007-06-08 - English

Clinical use of molecular markers in adult acute myeloid leukemia
2007-06-08 - English

New drugs for CLL
2007-06-08 - English

Human platelet alloantigens: heterogeneity of platelet alloantibodies
2007-06-08 - English

Recent advances in hemophilia management
2007-06-08 - English

Treatment of relapsing / refractory patients with Hodgkin's lymphoma
2007-06-08 - English

Laboratory diagnosis of neonatal alloimmune thrombocytopenia
2007-06-08 - English

Tailoring the treatment for early-stage Hodgkin's lymphoma
2007-06-08 - English

Management of elderly patients with acute myeloid leukemia
2007-06-08 - English

Management of patients with imatinib resistance
2007-06-08 - English

To summarise the different definitions of response and resistance to Imatinib.
To understand the mechanism of resistance to Imatinib.
To review the preliminary data from pahse II studies of second generation TKI
To outline the management options for CML patients resistant to Imatinib

Gene therapy for hemophilia
2007-06-08 - English

Genome-wide approaches to identify new subtypes of acute myeloid leukemia (AML)
2007-06-08 - English

Molecular pathogenesis of myelodysplastic syndromes
2007-06-08 - English

Pathology and genetics of T-cell lymphomas
2007-06-08 - English

New developments in curative approaches in myelodysplasia
2007-06-08 - English

Epigenetic therapy in MDS
2007-06-08 - English

Immunotherapy of leukemia with TCR gene modified T cells
2007-06-08 - English

Novel drugs for the treatment of T-cell lymphoma
2007-06-08 - English

The molecular and cellular basis for immunotherapeutic intervention in malignant disease: dynamic imaging of the immune system
2007-06-08 - English

Hydroxyurea: benefits and risks in patients affected with sickle cell anemia
2007-06-08 - English

VKORC1: pharmacogenetics and oral anticoagulation
2007-06-08 - English

Multiple myeloma: diagnosis, staging and criteria of response
2007-06-08 - English

Novel treatment approaches in multiple myeloma
2007-06-08 - English

High-dose melphalan followed by autologous stem cell transplantation in the younger patients and oral melphalan-prednisone in the elderly have been considered the standard of care for the initial therapy of myeloma. Survival after transplant appears to be related to the...(more)

Venous thromboembolism in medical patients: stratification and prevention
2007-06-08 - English

Current treatment of T-cell lymphomas: are we making any progress?
2007-06-08 - English

Advances in myeloma biology: basis for new therapy
2007-06-08 - English

Hemolysis-associated pulmonary hypertension in sickle cell disease and thalassemia
2007-06-08 - English

1. Understand the role of intravascular hemolysis in the development of impaired nitric oxide bioavailability.
2. Understand the contribution of impaired nitric oxide bioavailability to pulmonary hypertension in sickle cell disease and thalassemia.
3. Understand the...(more)

Do arterial and venous thrombosis share common risk factors?
2007-06-08 - English

The role of molecular analysis in the investigation of inherited anemias
2007-06-08 - English

Genetics of T-cell acute lymphoblastic leukemia
2007-06-08 - English

Detection of minimal residual disease in adult patients with acute lymphoblastic leukemia: methodological advances and clinical significance
2007-06-08 - English

The contribution of asthma to sickle cell disease related morbidity and mortality
2007-06-08 - English

Thrombophilia: from single gene disorder to complex disease
2007-06-08 - English

Venous thrombosis (VT) is an episodic disease. Blood clots are formed in veins which obstruct the circulation of the blood locally or, after the formation of emboli, elsewhere in the circulation. Acute events can be treated effectively by anticoagulant treatment aiming at...(more)

Stem cell banking
2007-06-09 - English

Stem cell banking
2007-06-09 - English

Duplication of the myb oncogene in T-cell acute lymphoblastic leukemia
2007-06-09 - English

Primary allogeneic stem cell transplantation versus best available drug treatment in chronic myeloid leukemia
2007-06-09 - English

A molecular classification of leukaemia reveals MDS as a disease continuum with non-leukaemia and AML sub groups
2007-06-09 - English

A molecular classification of leukaemia reveals MDS as a disease continuum with non-leukaemia and AML sub groups.

Ken I. Mills1,2,7, Amanda F Gilkes1, Jesus M. Hernandez4,7, Wolf-Karsten Hofmann,5,, Alexander Kohlmann6, Mickey Williams6, Lothar Wieczorek6, Torsten...(more)

The JAK2 V617F mutation is present in a minority of human hematopoietic stem cells from patients with myeloproliferative disorders and does not modify their self-renewal properties
2007-06-09 - English

THE JAK2 V617F MUTATION IS PRESENT IN A MINORITY OF HUMAN HEMATOPOIETIC STEM CELLS FROM PATIENTS WITH MYELOPROLIFERATIVE DISORDERS AND DOES NOT MODIFY THEIR SELF-RENEWAL PROPERTIES

Chloé James, Fréderic Mazurier, Ronan Chaligne, Isabelle Lamrissi-Garcia, Sabrina Dupont,...(more)

Identification of the chromatin-remodeling protein SATB1 as a development-dependent long-range transcriptional regulator of the PU.1 gene
2007-06-09 - English

Optimizing anti-thrombotic treatment: the role of new and established agents
2007-06-09 - English

Globin gene transfer for red blood cell disorders, a paradigm for stem cell-based gene therapy
2007-06-09 - English

After viewing this presentation, the participant will be able to discuss:
- current status of genetic approaches to the treatment of [beta] thalassemia and sickle cell disease

Genomic instability in leukemia
2007-06-10 - English